Pacer Advisors
PBYI icon

Pacer Advisors’s Puma Biotechnology PBYI Stock Holding History

Pacer Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,837
Closed -$28K – 1509
2021
Q1 		$28K Sell
2,837
-598
-17% -$6.68K ﹤0.01% 1488
2020
Q4 		$35K Sell
3,435
-1,954
-36% -$19.8K ﹤0.01% 1448
2020
Q3 		$54K Buy
+5,389
New +$54.9K ﹤0.01% 1301
2018
Q4 		– Sell
-5,468
Closed -$251K – 908
2018
Q3 		$251K Buy
+5,468
New +$264K 0.01% 985
2018
Q1 		– Sell
-1,075
Closed -$106K – 1104
2017
Q4 		$106K Buy
+1,075
New +$120K 0.01% 956

Other funds holding PBYI

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Pacer Advisors's PBYI Position: Q2 2021 in Review

Pacer Advisors sold out of Puma Biotechnology (PBYI) in Q2 2021, closing a stake of 2,837 shares — an estimated $28K sold.

Pacer Advisors first reported a position in PBYI in Q4 2017 and held it in 5 quarters. The position peaked at $251K in Q3 2018. 120 funds tracked by Wall St. Rank hold PBYI as of Q2 2021.

  • Pacer Advisors reported no remaining Puma Biotechnology position as of Q2 2021 after selling out during the quarter.
  • Pacer Advisors sold 2,837 Puma Biotechnology shares in Q2 2021, an estimated $28K.
  • Pacer Advisors first reported a position in Puma Biotechnology in Q4 2017 and held it in 5 quarters.
  • Pacer Advisors's Puma Biotechnology position peaked at $251K in Q3 2018.
  • 120 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.